A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination with Atezolizumab Versus Fruquintinib in Patients with Advanced Microsatellite Stable Colorectal Cancer (NCT07235293)

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof Andrew Haydon

Key inclusion data

Participants have a histologically confirmed, inoperable, microsatellite stable and/or proficient mismatch repair colorectal carcinoma. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at time of Screening. Progressed on or is intolerant to treatment with Lonsurf ± bevacizumab. Prior treatment with no more than 3 lines of therapy. Measurable disease per RECIST v1.1. Life expectancy over 3 months.